Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedMalaria

Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1–CRM197 malaria transmission-blocking vaccine

Vaccine·

Puthupparampil V. Scaria, Beth Chen, Olga Muratova, Pinar Kemanli, Justin Y.A. Doritchamou, Lynn E. Lambert, Emma K. Barnafo, Kelly M. Rausch, David L. Narum, Umesh Shaligram, Gale Smith, Patrick E. Duffy

DOI
10.1016/j.vaccine.2026.128913
PMID
42456560
PMCID
OpenAlex
W7168257327
Study type
Journal article
Publisher
Elsevier BV
Article type
journal-article
Integrity
current

Why this research matters now

The findings provide preclinical formulation and manufacturing context for development of a Pfs230D1-CRM197 malaria transmission-blocking vaccine. The supplied evidence does not report human immunogenicity, transmission reduction, clinical effectiveness, or population-level impact.

01

Structured evidence summary

Research question

How do differing levels of sulfhydryl modification on Pfs230D1 and maleimide modification on CRM197 affect the molecular weight and immunogenicity of Pfs230D1-CRM197 conjugates?

Study design

The study generated a series of Pfs230D1-CRM197 conjugates with varied antigen and carrier modification levels, followed by a mouse immunogenicity study using Matrix-M adjuvant.

Population and setting

The reported immunogenicity evaluation was conducted in mice using Matrix-M-adjuvanted conjugates. No human population or clinical setting is described in the supplied abstract.

Main findings

Conjugate size and immunogenicity varied with the numbers of sulfhydryl and maleimide modifications applied to the antigen and carrier. A wide range of modification levels produced highly immunogenic Pfs230D1 conjugates in the mouse study.

Public-health relevance

The findings provide preclinical formulation and manufacturing context for development of a Pfs230D1-CRM197 malaria transmission-blocking vaccine. The supplied evidence does not report human immunogenicity, transmission reduction, clinical effectiveness, or population-level impact.

Important limitations

The supplied abstract describes a mouse immunogenicity study and does not provide human, clinical, or population-level outcomes. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.

GIDS interpretation

This article is discoverable as malaria vaccination and transmission-dynamics literature because it concerns a preclinical transmission-blocking vaccine candidate. It provides research context only and does not establish or confirm a live surveillance signal.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 8 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicevaluates interventionhas pathogen typehas pathogen typestudied population settinguses study design